{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:04:33Z","timestamp":1753891473480,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R38 HL150207"],"award-info":[{"award-number":["R38 HL150207"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Sarcoidosis is a multiorgan system granulomatous disease of unknown etiology. It is hypothesized that a combination of environmental, occupational, and\/or infectious factors provoke an immunological response in genetically susceptible individuals, resulting in a diversity of manifestations throughout the body. In the United States, cardiac sarcoidosis (CS) is diagnosed in 5% of patients with systemic sarcoidosis, however, autopsy results suggest that cardiac involvement may be present in &amp;gt; 50% of patients. CS is debilitating and significantly decreases quality of life and survival. Currently, there are no gold-standard clinical diagnostic or monitoring criteria for CS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified patients with a diagnosis of sarcoidosis who were seen at the Simmons Center from 2007 to 2020 who had a positive finding of CS documented with cardiovascular magnetic resonance (CMR) and\/or endomyocardial biopsy as found in the electronic health record. Medical records were independently reviewed for interpretation and diagnostic features of CS including late gadolinium enhancement (LGE) patterns, increased signal on T2-weighted imaging, and non-caseating granulomas, respectively. Extracardiac organ involvement, cardiac manifestations, comorbid conditions, treatment history, and vital status were also abstracted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 44 unique patients with evidence of CS out of 246 CMR reports and 9 endomyocardial biopsy pathology reports. The first eligible case was diagnosed in 2007. The majority of patients (73%) had pulmonary manifestations, followed by hepatic manifestations (23%), cutaneous involvement (23%), and urolithiasis (20%). Heart failure was the most common cardiac manifestation affecting 59% of patients. Of these, 39% had a documented left ventricular ejection fraction of &amp;lt; 50% on CMR. Fifty eight percent of patients had a conduction disease and 44% of patients had documented ventricular arrhythmias. Pharmacotherapy was usually initiated for extracardiac manifestations and 93% of patients had been prescribed prednisone. ICD implantation occurred in 43% of patients. Patients were followed up for a median of 5.4 (IQR: 2.4\u20138.5) years. The 10-year survival was 70%. In addition to age, cutaneous involvement was associated with an increased risk of death (age-adjusted OR 8.47, 95% CI = 1.11\u201364.73).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CMR is an important tool in the non-invasive diagnosis of CS. The presence of LGE on CMR in a pattern consistent with CS has been shown to be a predictor of mortality and likely contributed to a high proportion of patients undergoing ICD implantation to decrease risk of sudden cardiac death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical implications<\/jats:title><jats:p>Additional studies are necessary to develop robust criteria for the diagnosis of CS with CMR, assess the benefit of serial imaging for disease monitoring, and evaluate the effect of immunosuppression on disease progression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1051412","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T06:14:05Z","timestamp":1670912045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and survival of patients diagnosed with cardiac sarcoidosis: A case series"],"prefix":"10.3389","volume":"9","author":[{"given":"Tiffany L.","family":"Brazile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Saul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mehdi","family":"Nouraie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.5114\/aoms.2011.24118","article-title":"Cardiac sarcoidosis: a comprehensive review.","volume":"7","author":"Sekhri","year":"2011","journal-title":"Arch Med Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.mcna.2005.02.006","article-title":"Sarcoidosis.","volume":"89","author":"Cox","year":"2005","journal-title":"Med Clin North Am."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1513\/AnnalsATS.201511-760OC","article-title":"Sarcoidosis in America. analysis based on health care use.","volume":"13","author":"Baughman","year":"2016","journal-title":"Ann Am Thorac Soc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0272-5231(05)70412-3","article-title":"Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us?","volume":"18","author":"Hosoda","year":"1997","journal-title":"Clin Chest Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ahj.2004.10.006","article-title":"A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy.","volume":"150","author":"Ardehali","year":"2005","journal-title":"Am Heart J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1440-1827.1993.tb01148.x","article-title":"Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan.","volume":"43","author":"Iwai","year":"1993","journal-title":"Acta Pathol Jpn."},{"key":"B7","first-page":"167","article-title":"Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.","volume":"119","author":"Perry","year":"1995","journal-title":"Arch Pathol Lab Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","article-title":"Cardiac sarcoidosis.","volume":"68","author":"Birnie","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ahj.2020.02.008","article-title":"Performance of diagnostic criteria in patients clinically judged to have cardiac sarcoidosis: is it time to regroup?","volume":"223","author":"Ribeiro Neto","year":"2020","journal-title":"Am Heart J."},{"key":"B11","first-page":"50","article-title":"Cardiac sarcoidosis-state of the art review.","volume":"6","author":"Hulten","year":"2016","journal-title":"Cardiovasc Diagn Ther."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.119.009622","article-title":"Diagnostic accuracy of advanced imaging in cardiac sarcoidosis.","volume":"12","author":"Divakaran","year":"2019","journal-title":"Circ Cardiovasc Imaging."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.cjca.2013.02.004","article-title":"Corticosteroid therapy for cardiac sarcoidosis: a systematic review.","volume":"29","author":"Sadek","year":"2013","journal-title":"Can J Cardiol."},{"key":"B14","first-page":"1438","article-title":"[An epidemiological study of clustering of sarcoidosis cases].","volume":"52","author":"Hiraga","year":"1994","journal-title":"Nihon Rinsho."},{"key":"B15","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool.","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis- digest version.","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.000867","article-title":"Evaluation of known or suspected cardiac sarcoidosis.","volume":"9","author":"Blankstein","year":"2016","journal-title":"Circ Cardiovasc Imaging."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012715","article-title":"Cardiac sarcoidosis: a picture may be worth a thousand words, but do we need more?","volume":"8","author":"Patel","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7457369","article-title":"Cardiac magnetic resonance imaging for diagnosis of cardiac sarcoidosis: a meta-analysis.","volume":"2018","author":"Zhang","year":"2018","journal-title":"Can Respir J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation."},{"key":"B21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.chest.2016.08.1457","article-title":"Cardiac sarcoidosis: the impact of age and implanted devices on survival.","volume":"151","author":"Zhou","year":"2017","journal-title":"Chest."},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238391","article-title":"Cardiac sarcoidosis: a long term follow up study.","volume":"15","author":"Cacoub","year":"2020","journal-title":"PLoS One."},{"key":"B23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/clc.4960270409","article-title":"Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome.","volume":"27","author":"Furushima","year":"2004","journal-title":"Clin Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/europace\/eun110","article-title":"Ventricular tachyarrhythmia as a primary presentation of sarcoidosis.","volume":"10","author":"Uusimaa","year":"2008","journal-title":"Europace."},{"key":"B25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/HCO.0b013e32834e4c7c","article-title":"Arrhythmias in cardiac sarcoidosis: diagnosis and treatment.","volume":"27","author":"Nery","year":"2012","journal-title":"Curr Opin Cardiol."},{"key":"B26","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society.","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2012.12.017","article-title":"ACCF\/HRS\/AHA\/ASE\/HFSA\/SCAI\/SCCT\/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American college of cardiology foundation appropriate use criteria task force, heart rhythm society, American heart association, American society of echocardiography, heart failure society of America, society for cardiovascular angiography and interventions, Society of cardiovascular computed tomography, and society for cardiovascular magnetic resonance.","volume":"61","author":"Russo","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.cardfail.2017.05.012","article-title":"The ICD and shared decision making: nothing is ever easy.","volume":"23","author":"Goetz","year":"2017","journal-title":"J Card Fail."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1001\/jamainternmed.2014.3435","article-title":"Decision making at the time of ICD generator change: patients\u2019 perspectives.","volume":"174","author":"Lewis","year":"2014","journal-title":"JAMA Intern Med."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007844","article-title":"Hospitalization rates, prevalence of cardiovascular manifestations, and outcomes associated with sarcoidosis in the United States.","volume":"7","author":"Patel","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone.","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.003738","article-title":"Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance.","volume":"9","author":"Murtagh","year":"2016","journal-title":"Circ Cardiovasc Imaging."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1378\/chest.129.5.1246","article-title":"Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis.","volume":"129","author":"Handa","year":"2006","journal-title":"Chest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S0012-3692(15)37649-2","article-title":"Predicting mortality in patients with sarcoidosis awaiting lung transplantation.","volume":"124","author":"Shorr","year":"2003","journal-title":"Chest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1378\/chest.128.3.1483","article-title":"Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension.","volume":"128","author":"Sulica","year":"2005","journal-title":"Chest."},{"key":"B36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/thx.2005.042838","article-title":"Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.","volume":"61","author":"Nunes","year":"2006","journal-title":"Thorax."},{"key":"B37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.clindermatol.2007.03.004","article-title":"Cutaneous sarcoidosis: differential diagnosis.","volume":"25","author":"Fernandez-Faith","year":"2007","journal-title":"Clin Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"719.e1","DOI":"10.1016\/j.jaad.2012.02.003","article-title":"Sarcoidosis: a comprehensive review and update for the dermatologist: part II. extracutaneous disease.","volume":"66","author":"Haimovic","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1136\/hrt.2005.080481","article-title":"Cardiac sarcoidosis.","volume":"92","author":"Doughan","year":"2006","journal-title":"Heart."},{"key":"B40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.amjcard.2004.08.083","article-title":"Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis.","volume":"95","author":"Chiu","year":"2005","journal-title":"Am J Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT).","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs.","volume":"276","author":"Ballul","year":"2019","journal-title":"Int J Cardiol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1051412\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T06:14:13Z","timestamp":1670912053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1051412\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":42,"alternative-id":["10.3389\/fmed.2022.1051412"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1051412","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"article-number":"1051412"}}